miRNA Expression Profiling

miRNA 表达谱

• 批准号: 7109973
• 负责人: DAVID M BROWN
• 金额: $ 36.38万
• 依托单位: AMBION DIAGNOSTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7109973
• 关键词: RNA; neoplasm /cancer; tissues

DESCRIPTION (provided by applicant): During Phase I of our research project, we developed a microarray system that can be used to measure the expression of known miRNAs in human, mouse, or rat samples. We used the microarray system to analyze tumor and normal adjacent tissues from patients with lung, colon, breast, prostate, bladder, thyroid, and pancreas cancer. Each tumor type could be readily distinguished from the accompanying normal samples based on the expression levels of 3-10 miRNAs. While each different tumor type was characterized by its own unique miRNA profile, it is interesting to note that several miRNAs appear to be up- or down-regulated in almost all tumor samples relative to normal adjacent tissue samples. This suggests that specific miRNAs might play roles in tumor suppression. Putative mRNA targets for a number of these miRNAs are known oncogenes providing a potential link with oncogenesis. We have verified that the expression of two well- known oncogenes is regulated by one of the miRNAs that was found to be differentially expressed in cancer samples, providing a potential link between reduced miRNA expression and oncogenesis. During Phase II of our research project, we will create methods for, isolating, amplifying, and labeling the miRNA in a sample to enable the analysis of small samples like those that result from needle biopsies and laser capture microdissection (LCM). The amplification method will facilitate studies of miRNA expression in specific types of cancer cells within the tumors of cancer patients and allow researchers to better understand how miRNAs contribute to oncogenesis. We will use the procedure that we develop to analyze LCM samples from lung and colon cancer tumors and normal adjacent tissues to verify that miRNA expression does differ between cell types in tissues.

描述（由申请人提供）：在我们研究项目的I期中，我们开发了一个微阵列系统，该系统可用于测量人，小鼠或大鼠样品中已知的miRNA的表达。我们使用微阵列系统来分析肺，结肠，乳腺癌，前列腺，膀胱，甲状腺和胰腺癌患者的肿瘤和正常邻近组织。每种肿瘤类型都可以根据3-10 miRNA的表达水平与伴随的正常样品区分开。虽然每种不同的肿瘤类型的特征都具有其独特的miRNA谱，但有趣的是，几乎所有肿瘤样品中的几个miRNA似乎相对于正常的邻近组织样品而在几乎所有肿瘤样品中都被上调。这表明特定的miRNA可能在肿瘤抑制中起作用。许多这些miRNA的假定mRNA靶标是已知的肿瘤基因，可与肿瘤发生有潜在的联系。我们已经证实，两种众所周知的肿瘤的表达受到一种miRNA的调节，其中一种被发现在癌症样品中差异表达，从而在降低miRNA表达和肿瘤发生之间提供了潜在的联系。在我们的研究项目的第二阶段中，我们将创建用于分离，放大和标记样品中miRNA的方法，以实现对小样品的分析，例如针头活检和激光捕获微分辨率（LCM）的小样本。扩增方法将促进癌症患者肿瘤中特定类型的癌细胞中miRNA表达的研究，并使研究人员能够更好地了解miRNA如何促进肿瘤发生。我们将使用开发的程序来分析来自肺癌和结肠癌肿瘤和正常相邻组织的LCM样品，以验证miRNA表达在组织中的细胞类型之间确实有所不同。